Company Description
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.
The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.
The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 29, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. James Brian Windsor Ph.D. |
Contact Details
Address: 12407 N. Mopac Expy., Suite 250 #390 Austin, Texas 78758 United States | |
| Phone | (737) 802-1989 |
| Website | aileronrx.com |
Stock Details
| Ticker Symbol | ALRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420565 |
| CUSIP Number | 00887A105 |
| ISIN Number | US00887A2042 |
| Employer ID | 13-4196017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Brian Windsor Ph.D. | Chief Executive Officer and Director |
| Charles T. Garner | Principal Financial and Acconting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Mar 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |